Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27317688 | 0.84 | MEN1 (0.50) | SMN1; SMN2ALDH1A1MAPTTNFRSF1A | |
| SCHEMBL20970598 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL4735623 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL25311659 | 0.78 | PKM (0.53) | ALDH1A1MAPTRAB9AL3MBTL1KDM4E | |
| SCHEMBL8431663 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL25314500 | 0.78 | MEN1 (0.38) | SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL8636608 | 0.76 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL14999454 | 0.74 | SLC6A5 (0.59) | SLC6A5 | |
| SCHEMBL9680841 | 0.73 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1978463 | 0.73 | TSHR (0.47) | ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11525024-B2 | Bio-based polymers from raw lignocellulosic biomass | UNIVERSITY OF DELAWARE (US) | 2022-12-13 | — | — | US | claimed |
| US-20250250384-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | UNIVERSITY OF DELAWARE | 2025-08-07 | — | — | US | disclosed |
| US-12291592-B2 | Ion-conducting bio-based polymers from raw lignocellulosic biomass | UNIVERSITY OF DELAWARE (US) | 2025-05-06 | — | — | US | disclosed |
| US-20230113164-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | UNIVERSITY OF DELAWARE (US) | 2023-04-13 | — | — | US | disclosed |
| US-11525024-B2 | Bio-based polymers from raw lignocellulosic biomass | UNIVERSITY OF DELAWARE (US) | 2022-12-13 | — | — | US | disclosed |
| US-20190144590-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | UNIVERSITY OF DELAWARE (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291592-B2 | Ion-conducting bio-based polymers from raw lignocellulosic biomass | ME1, FHIT, BOLA2; BOLA2B | SMN1; SMN2 4691/4885ALDH1A1 317/4885MAPT 3724/4885 |
| US-20250250384-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | ME1, BLVRB, FHIT | SMN1; SMN2 4722/4885ALDH1A1 224/4885MAPT 3447/4885 |
| US-20230113164-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | ME1, BLVRB, FHIT | SMN1; SMN2 4724/4885ALDH1A1 333/4885MAPT 3267/4885 |
| US-11525024-B2 | Bio-based polymers from raw lignocellulosic biomass | ME1, BLVRB, PLOD1 | SMN1; SMN2 4600/4885ALDH1A1 280/4885MAPT 3336/4885 |
| US-20190144590-A1 | BIO-BASED POLYMERS FROM RAW LIGNOCELLULOSIC BIOMASS | ME1, BLVRB, PLOD1 | SMN1; SMN2 4600/4885ALDH1A1 280/4885MAPT 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.